L-cysteine as a regulator for arsenic-mediated cancer-promoting and anti-cancer effects

Toxicology in Vitro

Volumn 25, Issue 3, 2011, Pages 623-629

  Kato, Masashi ^a   Kumasaka, Mayuko Y ^a   Takeda, Kozue ^a   Hossain, Khaled ^a   Iida, Machiko ^a   Yajima, Ichiro ^a   Goto, Yuji ^a   Ohgami, Nobutaka ^a  

^a CHUBU UNIVERSITY   (Japan)

Author keywords

Arsenic; Cancer; L cysteine; RET tyrosine kinase

Indexed keywords

ARSENIC; CYSTEINE; GELATINASE A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MEN2A; PROTEIN RET; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL STRAIN 3T3; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME RELEASE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN EXPRESSION; TUMOR PROMOTION;

ANIMALS; ANTICARCINOGENIC AGENTS; ARSENITES; CARCINOGENS, ENVIRONMENTAL; CELL SURVIVAL; CYSTEINE; DRUG INTERACTIONS; ENZYME INHIBITORS; MATRIX METALLOPROTEINASE 2; MICE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NIH 3T3 CELLS; POLY(ADP-RIBOSE) POLYMERASES; SODIUM COMPOUNDS; TRANSFECTION;

EID: 79952040567     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.12.012     Document Type: Article

References (34)

1. Achanzar W.E., Brambila E.M., Diwan B.A., Webber M.M., Waalkes M.P. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl. Cancer Inst. 2002, 94:1888-1891.
2. Asai N., Iwashita T., Matsuyama M., Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell Biol. 1995, 15:1613-1619.
3. Azzam H.S., Arand G., Lippman M.E., Thompson E.W. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J. Natl. Cancer Inst. 1993, 85:1758-1764.
4. Chen Y., Graziano J.H., Parvez F., Hussain I., Momotaj H., van Geen A., Howe G.R., Ahsan H. Modification of risk of arsenic-induced skin lesions by sunlight exposure, smoking, and occupational exposures in Bangladesh. Epidemiology 2006, 17:459-467.
5. Chiariello M., Visconti R., Carlomagno F., Melillo R.M., Bucci C., de Franciscis V., Fox G.M., Jing S., Coso O.A., Gutkind J.S., Fusco A., Santoro M. Signalling of the Ret receptor tyrosine kinase through the c-JUN NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by RET. Oncogene 1998, 16:2435-2445.
6. D'Agostini F., Balansky R.M., Camoirano A., De Flora S. Modulation of light-induced skin tumors by N-acetylcysteine and/or ascorbic acid in hairless mice. Carcinogenesis 2005, 26:657-664.
7. Dalberg K., Eriksson E., Enberg U., Kjellman M., Backdahl M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J. Surg. 2000, 24:334-340.
8. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 2007, 33:542-564.
9. Gault A.G., Rowland H.A., Charnock J.M., Wogelius R.A., Gomez-Morilla I., Vong S., Leng M., Samreth S., Sampson M.L., Polya D.A. Arsenic in hair and nails of individuals exposed to arsenic-rich groundwaters in Kandal province, Cambodia. Sci. Total Environ. 2008, 393:168-176.
10. Hinwood A.L., Sim M.R., Jolley D., de Klerk N., Bastone E.B., Gerostamoulos J., Drummer O.H. Hair and toenail arsenic concentrations of residents living in areas with high environmental arsenic concentrations. Environ. Health Perspect. 2003, 111:187-193.
11. Jainchill J.L., Aaronson S.A., Todaro G.J. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J. Virol. 1969, 4:549-553.
12. Iwamoto T., Takahashi M., Ito M., Hamaguchi M., Isobe K., Misawa N., Asai J., Yoshida T., Nakashima I. Oncogenicity of the ret transforming gene in MMTV/RET transgenic mice. Oncogene 1990, 5:535-542.
13. Kato M., Hossain K., Iida M., Sato H., Uemura N., Goto Y. Arsenic enhances matrix metalloproteinase-14 expression in fibroblasts. J. Toxicol. Environ. Health A 2008, 71:1053-1055.
14. Kato M., Iwashita T., Takeda K., Akhand A.A., Liu W., Yoshihara M., Asai N., Suzuki H., Takahashi M., Nakashima I. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic RET tyrosine kinases. Mol. Biol. Cell 2000, 11:93-101.
15. Kato M., Liu W., Akhand A.A., Hossain K., Takeda K., Takahashi M., Nakashima I. Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in RFP-RET-transgenic mice. J. Invest. Dermatol. 2000, 115:1157-1158.
16. Kato M., Ohgami N., Kawamoto Y., Tsuzuki T., Hossain K., Yanagishita T., Ohshima Y., Tsuboi H., Yamanoshita O., Matsumoto Y., Takahashi M., Nakashima I. Protective effect of hyperpigmented skin on UV-mediated cutaneous cancer development. J. Invest. Dermatol. 2007, 127:1244-1249.
17. Kato M., Takahashi M., Akhand A.A., Liu W., Dai Y., Shimizu S., Iwamoto T., Suzuki H., Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene 1998, 17:1885-1888.
18. Kato M., Takeda K., Hossain K., Thang N.D., Kaneko Y., Kumasaka M., Yamanoshita O., Uemura N., Takahashi M., Ohgami N., Kawamoto Y. A redox-linked novel pathway for arsenic-mediated RET tyrosine kinase activation. J. Cell Biochem. 2010, 110:399-407.
19. Kato M., Takeda K., Kawamoto Y., Iwashita T., Akhand A.A., Senga T., Yamamoto M., Sobue G., Hamaguchi M., Takahashi M., Nakashima I. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine. Cancer Res. 2002, 62:2414-2422.
20. Kato M., Takeda K., Kawamoto Y., Tsuzuki T., Hossain K., Tamakoshi A., Kunisada T., Kambayashi Y., Ogino K., Suzuki H., Takahashi M., Nakashima I. C-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res. 2004, 64:801-806.
21. Kato M., Wickner W. Vam10p defines a Sec18p-independent step of priming that allows yeast vacuole tethering. Proc. Natl. Acad. Sci. USA 2003, 100:6398-6403.
22. Kawai K., Iwashita T., Murakami H., Hiraiwa N., Yoshiki A., Kusakabe M., Ono K., Iida K., Nakayama A., Takahashi M. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res. 2000, 60:5254-5260.
23. Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M., Suzuki H., Takahashi M., Nakashima I. Identification of RET autophosphorylation sites by mass spectrometry. J. Biol. Chem. 2004, 279:14213-14224.
24. Mandal B.K., Suzuki K.T. Arsenic round the world: a review. Talanta 2002, 58:201-235.
25. Noel A.C., Polette M., Lewalle J.M., Munaut C., Emonard H.P., Birembaut P., Foidart J.M. Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells. Int. J. Cancer 1994, 56:331-336.
26. Ohshima Y., Yajima I., Takeda K., Lida M., Kumasaka M., Matsumoto Y., Kato M. c-RET molecule in maligant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS One 2010, 5:e10279.
27. Park M.T., Kang Y.H., Park I.C., Kim C.H., Lee Y.S., Chung H.Y., Lee S.J. Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells. Mol. Cancer Ther. 2007, 6:82-92.
28. Schuchardt A., D'Agati V., Larsson-Blomberg L., Costantini F., Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature 1994, 367:380-383.
29. Smith A.H., Hopenhayn-Rich C., Bates M.N., Goeden H.M., Hertz-Picciotto I., Duggan H.M., Wood R., Kosnett M.J., Smith M.T. Cancer risks from arsenic in drinking water. Environ. Health Perspect. 1992, 97:259-267.
30. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339:1341-1348.
31. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990, 9:289-303.
32. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 1993, 9:541-573.
33. Vahter M.E., Li L., Nermell B., Rahman A., El Arifeen S., Rahman M., Persson L.A., Ekstrom E.C. Arsenic exposure in pregnancy: a population-based study in Matlab, Bangladesh. J. Health Popul. Nutr. 2006, 24:236-245.
34. Wang F.R., Lou Y.Q., Lu D.P. A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi 2005, 44:730-733.